MoonLake Immunotherapeutics Posts Strong Phase 3 Psoriatic Arthritis Data, Bolsters Cash Position
The clinical-stage biotech reported sonelokimab achieved a 42.1% ACR50 response rate in its first Phase 3 psoriatic arthritis readout, while its cash reserves swelled to $537 million following a significant equity raise.
MoonLake Immunotherapeutics (MLTX) reported its first Phase 3 topline results for sonelokimab in psoriatic arthritis, with the drug achieving an ACR50 response rate of 42.1% and an ACR20 rate of 66.5% at Week 16 in bio-naïve patients. The clinical-stage immunology company also disclosed a substantial strengthening of its balance sheet during the second quarter of 2026, driven by a capital raise that added roughly $179 million in cash.
The Phase 3 IZAR-1 trial data represent a critical milestone for MoonLake as it seeks to establish sonelokimab across multiple inflammatory indications. In addition to the ACR endpoints, the drug achieved a minimal disease activity rate of 41.2% and a PASI90 response of 61% at Week 16 with the 60 mg induction dose in bio-naïve patients. The company is advancing sonelokimab through a broader clinical program, with the IZAR-2 trial in TNF-refractory psoriatic arthritis patients expected to complete enrollment in the third quarter of 2026 and P-OLARIS trial results anticipated by late 2026 or early 2027.
MoonLake's cash, cash equivalents and short-term marketable debt securities rose to $537.0 million as of June 30, up from $357.9 million at the end of the first quarter. Cash and equivalents alone surged to $477.9 million from $298.5 million, a 60% sequential jump that largely reflected proceeds from an equity offering. Shares outstanding increased to 83.6 million from 72.1 million during the quarter, indicating the issuance of approximately 11.5 million new shares.
The company reiterated its cash runway guidance to mid-2028 and noted that up to $400 million in a non-dilutive debt facility with Hercules Capital remains available. Total assets climbed to $573.9 million from $400.4 million at the prior quarter-end, while total current assets rose to $570.0 million from $396.6 million.
Operating expenses moved lower sequentially. Research and development costs declined to $50.2 million in the second quarter from $54.5 million in the first, a decrease of approximately 8%. General and administrative expenses fell to $11.4 million from $15.5 million, a drop driven primarily by $4.8 million in accelerated expense recognition recorded in the first quarter related to the voluntary cancellation of unvested stock option awards.
Accrued expenses and other current liabilities rose to $27.1 million from $21.8 million, a 24% increase, while trade and other payables decreased to $17.0 million from $23.4 million.
On the regulatory front, MoonLake confirmed its biologics license application submission for sonelokimab in hidradenitis suppurativa remains on track for the end of September 2026, with a PDUFA date allocation expected by late November 2026, consistent with the timeline the company outlined in the prior quarter. Enrollment in the palmoplantar pustulosis trial is expected in the second half of 2026.